Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the ...
– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumor Type (Lung, Thyroid, Pancreas), or Prior Multikinase Inhibitor (MKI) …